Header Logo

Connection

PAOLO ANDERLINI to Transplantation, Autologous

Back to Details
This is a "connection" page, showing publications PAOLO ANDERLINI has written about Transplantation, Autologous.
PAOLO ANDERLINI
Connection Strength
0.748
Transplantation, Autologous
  1. Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2017 Jul; 23(7):1059-1063.
    View in: PubMed
    Score: 0.099
  2. Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia. Leuk Lymphoma. 2011 Jan; 52(1):137-41.
    View in: PubMed
    Score: 0.063
  3. Allogeneic peripheral blood stem cell collection as of 2008. Transfus Apher Sci. 2008 Jun; 38(3):219-27.
    View in: PubMed
    Score: 0.054
  4. Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. Blood Adv. 2022 04 12; 6(7):2267-2274.
    View in: PubMed
    Score: 0.035
  5. Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): current status. Cytotherapy. 2002; 4(3):241-51.
    View in: PubMed
    Score: 0.034
  6. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res. 2021 11 01; 27(21):5847-5856.
    View in: PubMed
    Score: 0.034
  7. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2021 05; 27(5):404.e1-404.e5.
    View in: PubMed
    Score: 0.032
  8. Can we cure refractory Hodgkin's lymphoma with transplantation? Bone Marrow Transplant. 2021 01; 56(1):278-281.
    View in: PubMed
    Score: 0.031
  9. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609.
    View in: PubMed
    Score: 0.026
  10. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol. 1996 Jul; 94(1):155-8.
    View in: PubMed
    Score: 0.024
  11. Treatment of acute myelogenous leukemia. N Engl J Med. 1995 Jun 22; 332(25):1717; author reply 1718-9.
    View in: PubMed
    Score: 0.022
  12. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20.
    View in: PubMed
    Score: 0.022
  13. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol. 2013 Sep; 88(9):754-7.
    View in: PubMed
    Score: 0.019
  14. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer. 2013 Sep 15; 119(18):3318-25.
    View in: PubMed
    Score: 0.019
  15. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant. 2013 Jun; 19(6):991-4.
    View in: PubMed
    Score: 0.019
  16. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013 Mar; 19(3):410-7.
    View in: PubMed
    Score: 0.018
  17. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86.
    View in: PubMed
    Score: 0.018
  18. Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan; 53(1):118-22.
    View in: PubMed
    Score: 0.017
  19. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant. 2011 Apr; 46(4):510-5.
    View in: PubMed
    Score: 0.016
  20. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol. 2009 Jun; 84(6):335-7.
    View in: PubMed
    Score: 0.014
  21. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23.
    View in: PubMed
    Score: 0.014
  22. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009 Apr 30; 113(18):4144-52.
    View in: PubMed
    Score: 0.014
  23. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008 Dec; 14(12):1401-7.
    View in: PubMed
    Score: 0.014
  24. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol. 2008 Jun; 19(6):1166-71.
    View in: PubMed
    Score: 0.013
  25. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1066-72.
    View in: PubMed
    Score: 0.013
  26. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2007 Sep; 40(5):431-5.
    View in: PubMed
    Score: 0.013
  27. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2005 Apr 01; 23(10):2240-7.
    View in: PubMed
    Score: 0.011
  28. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant. 2003 Jun; 9(6):405-13.
    View in: PubMed
    Score: 0.009
  29. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant. 2001 Aug; 28(3):271-5.
    View in: PubMed
    Score: 0.008
  30. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001 Apr; 27(8):821-8.
    View in: PubMed
    Score: 0.008
  31. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant. 2000 Jun; 25(11):1137-40.
    View in: PubMed
    Score: 0.008
  32. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.